GPRO Related
-
Canaccord Genuity Maintains a 'Buy' on Hologic (HOLX); Looking for a Dip
-
Needham & Company Reiterates a 'Buy' on Hologic (HOLX); Waiting 'Til November for GPRO Insight
-
SolarWinds (SWI) to Replace Gen-Probe in MidCap 400; HealthStream (HSTM) to Join SmallCap 600
-
Hologic (HOLX) Prices $1B Debt Offering in Connection with Gen-Probe (GPRO) Acquisition
-
Hologic (HOLX), Gen-Probe (GPRO) Update on Pending Merger; Hologic Preliminary Q3 EPS In-Line w/ Views
-
Jefferies Analysts Hot for Hologic (HOLX)
-
Top 10 News 4/30-5/4: Jobs Report Disappoints; Facebook IPO Terms Set; The Chesapeake Saga Continues...
-
Baird Downgrades Gen-Probe (GPRO) to Neutral
-
Cantor Fitzgerald Maintains a 'Hold' on Hologic (HOLX); Acquisition Overshadows Challenging Quarter
-
RBC Capital Downgrades Gen-Probe (GPRO) to Sector Perform
-
ThinkEquity Downgrades Gen-Probe (GPRO) to Hold
-
Raymond James Downgrades Gen-Probe (GPRO) to Market Perform
-
Dougherty & Co Downgrades Hologic (HOLX) to Neutral; Four Reasons Not To Like The Deal
-
Canaccord Genuity Maintains a 'Buy' on Hologic (HOLX); Now Largest Pure-Play in Molecular Diagnostics With GPRO Acquisition
-
Needham & Company Maintains a 'Buy' on Hologic (HOLX); Qtr In-line; Acquisition on Gen-Probe is Transformational
-
Market Wrap: Microsoft Did It All for the NOOK-ie; Dow on One-Year Win Streak...Nearly; Merger Monday!
-
Piper Jaffray Downgrades Gen-Probe (GPRO) to Neutral
-
Morning Movers 04/30: (BKS) (EDS) (IFT) (DMD) Higher; (PAY) (TSYS) (HUSA) Lower
-
Notable Mergers and Acquisitions of the Day 04/30: (BKS)/(MSFT) (SUN)/(ETP) (HOLX)/(GPRO)
-
Pre-Open Movers 4/30: (BKS) (DMD) (SUN) Higher; (LDK) (SOHU) (HUM) Lower (more...)
-
Qiagen (QGEN) Could Be on Watch Following Gen-Probe Takeover
-
Gen-Probe, Inc. (GPRO) Tops Q1 EPS by 4c
-
Hologic (HOLX) to Acquire Gen-Probe (GPRO) in $3.7B Deal
-
Barclays on U.S. Diagnostics: Q1 Earnings Preview
-
Canaccord Genuity on Life Sciences/Biomedical Devices & Services: Pipelines To Lead Way Through Q1
-
Jefferies Maintains Bullish Stance on Gen-Probe (GPRO) After Survey
-
Gen-Probe (GPRO) Appoints New SVP, VP, and IR Director
-
FDA approves Gen-Probe's (GPRO) PROGENSA(R) PCA3 Assay
-
Canaccord Genuity Reiterates a 'Buy' on Gen-Probe (GPRO); Good Q4; Solid Growth Prospects
-
Jefferies Raises Est./PT on Gen-Probe (GPRO) After Q4 Results and Accelerating Core Revenue Growth Trajectory
-
Gen-Probe, Inc. (GPRO) Tops Q4 EPS by 3c, Sales Fall Inline
-
Trading Radar for 02/13: Napco (NSSC), Fidelity (FIS), Limelight Networks (LLNW), Health Management Associates (HMA) Report
-
Gen-Probe (GPRO) Sees Double-Digit Revs Growth in FY12 on New Product Launches
-
RBC Capital Upgrades Gen-Probe (GPRO) to Outperform
-
ThinkEquity Starts Gen-Probe (GPRO) at Buy
-
Deutsche Bank Starts Gen-Probe (GPRO) at Buy; Consummate Molecular Diagnostics 'Pro'
-
Barclays 2012 Top Picks: Becoming Somewhat More Optimistic - Signs of Progress, Growth and Soft Landings
-
ThinkEquity Starts Gen-Probe (GPRO) at Buy
-
Gen-Probe (GPRO) Chair Nordhoff to Retire, CEO Hull to Assume Role
-
Canaccord Genuity Reiterates a 'Buy' on Gen-Probe (GPRO); HPV Garnering Attention
-
Canaccord Genuity reiterates a 'Buy' on Gen-Probe (GPRO); Solid Q3 - Focus Shifts to Marketing HPV Assay in US
-
Gen-Probe, Inc. (GPRO) Tops Q3 EPS by 3c; Trims Top-End of FY11 Outlook; Authorizes $100M Buyback
-
Trading Radar for 11/02: MasterCard (MA), Level 3 (LVLT), Clearwire (CLWR), MEMC Electronic Materials (WFR), Avis Budget (CAR) Report
-
Gen-Probe (GPRO) Gets FDA Approval for APTIMA HPV Assay
-
Barclays on U.S. Diagnostics: Policy, Macro Overhang Persists in Q3
-
Lazard Capital Starts Gen-Probe (GPRO) at Neutral
-
Wellington Raises Stake in Gen-Probe, Inc. (GPRO) to 10.17%
-
UPDATE - Canaccord Genuity Upgraded Gen-Probe (GPRO) to Buy; Outlook still attractive
-
Canaccord Genuity Upgrades Gen-Probe (GPRO) to Buy
-
Gen Probe (GPRO) Discloses Postponed FDA Panel Review of Progensa
Back to GPRO Stock Lookup
